CAR T cell therapy has transformed blood cancer treatment, but success in solid tumors remains limited by major challenges such as on-target/off-tumor toxicity, poor tumor infiltration, and an ...

Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy blood-forming cells. If the disease recurs after treatment or fails to respond, CAR ...

A rigorous medical journey ends in a breakthrough, in the form of CAR-T therapy, achieving a rare, hard-won cancer-free result.

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...